Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...
Corbus Pharmaceuticals Holdings, Inc. is a Phas...
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to ...
Dermira is a biopharmaceutical company dedicate...
Dyadic International, Inc. is a global biotechnology company based in Jupiter, Flo...
Dyadic International, Inc. is a global biotechn...
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...
Epizyme, Inc. is a clinical stage biopharmaceut...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a specialty clinical-stage pharmaceuti...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a s...
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical com...
Founded in Lyon, France in 2004, ERYTECH is a c...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Join the National Investor Network and get the latest information with your interests in mind.